Journal of Geriatric Psychiatry and Neurology

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Free Access - Register Here

SAGETRACK

Sign In to gain access to subscriptions and/or personal tools.
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wylie, M. E.
Right arrow Articles by Reynolds, C. F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wylie, M. E.
Right arrow Articles by Reynolds, C. F.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?
Journal of Geriatric Psychiatry and Neurology, Vol. 13, No. 1, 43-48 (2000)
DOI: 10.1177/089198870001300107

Fluvoxamine Pharmacotherapy of Anxiety Disorders in Later Life: Preliminary Open-Trial Data

Mary E. Wylie, MD

Mark D. Miller, MD

M. Katherine Shear, MD

John T. Little, MD

Benoit H. Mulsant, MD

Bruce G. Pollock, MD, PhD

Charles F. Reynolds, MD

The authors present data from an open trial of fluvoxamine (median daily dosage: 200 mg) in the treatment of generalized anxiety disorder, panic disorder, and obsessive-compulsive disorder in 19 older outpatients (mean age = 66.8). Of the 12 subjects completing the 21-week trial, 8 achieved a good response (50% reduction in symptom measures) and 7 were rated as much or very much improved. Fluvoxamine pharmacotherapy also had a significant effect in reducing comorbid depressive symptoms and in increasing levels of functioning. These data support the effectiveness of fluvoxamine in older subjects with anxiety disorders (particularly generalized anxiety disorder) and warrant further double-blind, placebo-controlled evaluation. (J Geriatr Psychiatry Neurol 2000; 13:43—48).


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 AJGPHome page
M. Pinquart and P. R. Duberstein
Treatment of Anxiety Disorders in Older Adults: A Meta-analytic Comparison of Behavioral and Pharmacological Interventions
Am J Geriatr Psychiatry, August 1, 2007; 15(8): 639 - 651.
[Abstract] [Full Text] [PDF]

Home page
 APPI Online CMEHome page
References
PsychiatryOnline CME, May 1, 2007; 2007(1): 2 - 2.
[Full Text]

Home page
 AJGPHome page
E. J. Lenze, B. H. Mulsant, J. Mohlman, M. K. Shear, M. A. Dew, R. Schulz, M. D. Miller, B. Tracey, and C. F. Reynolds III
Generalized Anxiety Disorder in Late Life: Lifetime Course and Comorbidity With Major Depressive Disorder
Am J Geriatr Psychiatry, January 1, 2005; 13(1): 77 - 80.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. PsychiatryHome page
E. J. Lenze, B. H. Mulsant, M. K. Shear, M. A. Dew, M. D. Miller, B. G. Pollock, P. Houck, B. Tracey, and C. F. Reynolds III
Efficacy and Tolerability of Citalopram in the Treatment of Late-Life Anxiety Disorders: Results From an 8-Week Randomized, Placebo-Controlled Trial
Am J Psychiatry, January 1, 2005; 162(1): 146 - 150.
[Abstract] [Full Text] [PDF]